Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Applied DNA Sciences Inc.

    NASDAQ: APDN · Real-Time Price · USD
    5.11
    0.28 (5.80%)
    At close: Jun 30, 2025, 3:59 PM
    4.57
    -10.57%
    After-hours: Jun 30, 2025, 07:23 PM EDT
    5.80%
    Bid 4.5
    Market Cap 2.65M
    Revenue (ttm) 3.79M
    Net Income (ttm) -31.28M
    EPS (ttm) 3730.95
    PE Ratio (ttm) n/a
    Forward PE -0.06
    Analyst Buy
    Ask 4.67
    Volume 69,156
    Avg. Volume (20D) 92,688
    Open 4.83
    Previous Close 4.83
    Day's Range 4.71 - 5.20
    52-Week Range 4.35 - 2655.00
    Beta 0.05

    About APDN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol APDN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for APDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Applied DNA Sciences Inc. is scheduled to release its earnings on Aug 7, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -36.86%
    Applied DNA Sciences shares are trading lower afte... Unlock content with Pro Subscription
    1 month ago
    -17.28%
    Applied DNA Sciences shares are trading lower. The company reported Q2 financial results.
    news image

    16 hours ago · accessnewswire.com

    Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx

    - Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth - STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDA...

    news image

    1 week ago · accessnewswire.com

    Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward

    President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or...

    news image

    2 weeks ago · accessnewswire.com

    Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August

    STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resu...

    news image

    1 month ago · accessnewswire.com

    Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

    STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec...

    news image

    1 month ago · accessnewswire.com

    Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

    - Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for  June ...

    news image

    1 month ago · accessnewswire.com

    Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3

    STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will relea...

    news image

    2 months ago · accessnewswire.com

    Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

    - Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company")...

    news image

    2 months ago · accessnewswire.com

    Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

    STONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a...

    news image

    3 months ago · accessnewswire.com

    Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement

    - Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDA...

    Add to Watchlist